Key Takeaways
- Disappointing quarter, weather-driven: Q2 FY26 was "very disappointing" as a phenomenally bad summer crushed air cooler demand across the entire industry; Symphony's decline was in sync with the market.
- RTY portfolio provided a floor: Round The Year products contributed ~21% of Q2 top line and ~26% of trailing 12 months, cushioning the seasonal collapse.
- Channel inventory overhang is clearing: High trade inventory from a subdued summer is normalizing; by end of Q3, both mindset and stock levels should settle closer to historical means.
- Margins hit by operating deleverage: EBITDA margin declined mainly on lower volumes, with a minor mix effect from mass-market product launches that management views as absolute-value accretive.
- What to watch next quarter: Whether channel inventory normalization translates into restocking demand, the pace of GSK China loan and IPR recoveries, and any concrete progress on the Mexico/Australia divestment process.
The Summer Shock: What Happened in Q2
- Weather, not demand: Management attributed the decline entirely to a weak summer, stating demand, inventory, and sentiment are all functions of weather. One good month, they argued, could reset everything.
- Industry-wide degrowth: The entire air cooler industry shrank substantially; Symphony's performance tracked the market. The air conditioner and fan industries also declined but less sharply than air coolers.
- Historical precedent: Similar quarters have occurred over the past 11 years, and the company has always rebounded much stronger. H1 FY26 was still the third-highest performance in company history.
- Channel inventory distortion: Very high inventory levels in the trade channel caused the poor September quarter. Post-GST rate cut and festive demand, channel cash flow issues have substantially rationalized.
- Rest of World lumpiness: The revenue drop in Rest of World reflects timing: last year, Brazil sales were preponed into the September quarter. IMPCO Mexico and GSK China showed growth in the quarter.
Bakeri: "All because of weak summer. Nothing because of demand. The demand is because of the summer, the inventory is also because of the summer. That's all. The sentiment is also because of the summer. And one good month and this entire sentiment and inventory, everything can change. One good month, not even a one good summer."
RTY Portfolio: The Structural Hedge
- Saved the quarter: Round The Year products, including Large Space Venti cooling, Tower Fan, Kitchen Cooling Fan, Water Heaters, and exports from India, contributed ~21% of Q2 top line and ~26% of trailing 12 months.
- Growth trajectory intact: RTY delivered healthy double-digit growth, almost in line with the business plan. Management sees huge potential and is beefing up the dealer and distribution network for these products.
- Water heater expansion: Launched 8 new water heater models, 6 storage and 2 instant, broadening the non-seasonal portfolio ahead of winter demand.
- Strategic intent: The RTY push is part of a deliberate strategy to build resilience beyond seasonality, alongside prioritizing high-margin growth markets and export-led diversification.
Core Air Cooling: Defending Leadership
- Market share stable among organized players: Symphony's market share among national and organized sector brands remained stable. When the large unorganized sector of 100+ smaller players is included, all top players' shares shrink mechanically.
- Mass-market offensive: Launched 9 new Air Force range models, 3 to 7 SKUs, targeted at rural and semi-urban markets. This metal-to-plastic conversion play expands the addressable market.
- Super-premium balancing act: Launches like Silenzo and Arctic Circle sit at the top end. Management expects the mass-premium mix to net out: gross margin may dip 1-2 percentage points if the mass portfolio becomes significant, but absolute value will be accretive.
- Channel schemes deployed: Schemes designed for the current year's specific challenges have been offered to distributors and dealers, with a good chunk already in the market. A new scheme was launched in the current quarter to capture improved trade partner sentiment.
Kumar: "If this portfolio becomes a significant share of our total numbers, then at the GM level, maybe there is 1% or 2% point kind of impact. But at the absolute value level, this is going to be very clearly accretive."
International Subsidiaries: Clean-up in Progress
- GSK China turning the corner: Strong growth momentum sustained; the subsidiary is advancing toward becoming completely debt-free very shortly. Peak loan from Symphony India was ~₹61 crores, now down to ~₹27 crores, with full repayment expected in ensuing quarters.
- IPR payment flowing: Out of ₹45 crores owed, ₹22 crores has been paid by GSK China from sale proceeds to IMPCO Mexico. The remaining ~₹23 crores is expected in the December quarter.
- Pathway recovery update: An additional ₹4 crores was recovered in October, bringing total recovery to ₹8.5 crores. Legal steps are being aggressively pursued, with a charge created on valuable real estate held by promoters and the company.
- Divestment process underway: An information memorandum has been submitted for the Mexico and Australia subsidiaries. Letters of interest have been received and are being dealt with; quite a few parties have signed NDAs and are evaluating. Management called it too premature to share details.
- Australia transformation complete: The operational transformation has been executed; focus is now on increasing top line and profitability.
Margins & Financial Health
- Operating deleverage the main culprit: The EBITDA margin decline was driven primarily by lower volumes, with a secondary mix effect from launching mass-market products.
- Balance sheet strength: Company inventory is broadly in line with the previous year; the business model does not carry much inventory. Surplus treasury stands at ₹577 crores, and there was no impact on company working capital.
- Production scalability invested in: The company has built operational agility to ramp up production quickly in case of a strong summer, positioning for a demand snapback.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Channel inventory normalization | Mindset and stock levels to settle closer to historical means | By end of Q3 FY26 |
| GSK China IPR receipt | Remaining ~₹23 crores expected | December quarter (Q3 FY26) |
| GSK China loan repayment | ~₹27 crores outstanding to be fully paid off | Ensuing quarters |
| Pathway recovery | Legal steps pursued; charge created on promoter/company real estate | Ongoing (₹4 cr recovered in Oct) |
| Divestment (Mexico, Australia) | Information memorandum submitted; LOIs received; NDAs signed | No timeline (process underway) |
| Production readiness | Scalability and operational agility built for demand surge | Ahead of next summer |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Standalone revenue | ₹155 cr, down from ₹259 cr in Sept '24 |
| Standalone EBITDA | ₹27 cr, down from ₹72 cr |
| Standalone PAT | ₹28 cr, down from ₹67 cr |
| Standalone EBITDA margin | Declined mainly on account of operating deleverage |
| Consolidated revenue (continuing ops) | ₹163 cr, down from ₹289 cr |
| Consolidated EBITDA (continuing ops) | ₹25 cr, down from ₹76 cr |
| Consolidated PAT (continuing ops) | ₹25 cr |
| Consolidated PAT (total) | ₹19 cr |
| H1 FY26 standalone revenue | ₹384 cr |
| H1 FY26 standalone PAT | ~₹65 cr, down from ₹136 cr |
| Round-the-year product contribution | ~21% of Q2 top line, ~26% of trailing 12 months |
| Treasury (surplus funds) | ₹577 cr as on 30th Sept '25, versus ₹685 cr previously |
| Interim dividend | ₹1 per share (50%), total payout ~₹14 cr in H1 |
| GSK China revenue | ₹32 cr, up from ₹25 cr |
| IMPCO Mexico revenue | ₹17 cr, up from ₹10 cr |
| Climate Holdings (Australia) revenue | ₹35 cr, up from ₹30 cr |
| Discontinued ops PAT | negative ₹6 cr, improved from negative ₹14 cr in Sept '24 |
| Channel inventory (end of Q2) | Slightly higher than normal 25–30% of season sales |